News archive
Showing 772 results
September 2024
-
Media Release
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2 … -
Media Release
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1 … -
Media Release
Novartis begins construction of two new radioligand therapy facilities in the US, expanding its world-class RLT manufacturing and supply network
Indianapolis site expansion will establish in-house production of isotopes critical for production of radioligand therapies (RLTs) for cancer treatment New facility in California will be…
August 2024
-
Story Access to Healthcare
Negative impact of the IRA on patient access to innovative treatments
-
Statement
Novartis statement on Maximum Fair Price for Entresto
-
Media Release
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs.…
July 2024
-
Media Release
Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML
Priority Review based on ASC4FIRST Phase III study with Scemblix® data first to show significantly improved molecular response and a favorable safety and tolerability profile compared to standard… -
Story Hope
A Journey of Compassion: From Pharmacy to Oncology Sales
Novartis employee story journey into Oncology sales
-
Story Global Impact
Associate volunteers help make the 2023 multicultural teen corporate mentoring program a success
Novartis's annual mentoring program inspires over 100 students to shape the future of healthcare, offering direct interaction with industry leaders.
May 2024
-
Media Release
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs.… -
Media Release
Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease
Addition of Kisqali® (ribociclib) to endocrine therapy (ET) demonstrated a 28% risk reduction in invasive disease-free survival (iDFS) in subgroup of patients with node-negative (N0) disease… -
Media Release
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine)…